Vanda Pharmaceuticals (VNDA) Net Cash Flow (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Net Cash Flow data on file, last reported at -$30.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 426.16% year-over-year to -$30.8 million; the trailing twelve-month figure through Mar 2026 stood at -$57.7 million (down 334.92% YoY), and the FY2025 full-year result was -$17.5 million, up 47.55% from the prior year.
• Net Cash Flow fell to -$30.8 million in Q1 2026, from $14.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $219.1 million in Q1 2023 to a low of -$204.1 million in Q2 2023.
• A 5-year average of $105764.7 and a median of -$8.8 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 5078.73% in 2022 and slumped 2224.23% in 2023, its largest moves.
• Tracing VNDA's Net Cash Flow over 5 years: stood at $85.4 million in 2022, then tumbled by 155.61% to -$47.5 million in 2023, then surged by 104.25% to $2.0 million in 2024, then jumped by 632.76% to $14.8 million in 2025, then tumbled by 307.71% to -$30.8 million in 2026.
• Business Quant data shows VNDA's Net Cash Flow at -$30.8 million in Q1 2026, $14.8 million in Q4 2025, and -$10.8 million in Q3 2025.